We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Biogen Inc | TG:IDP | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | |
---|---|---|---|---|---|
-0.80001 | -0.53% | 150.45 | 150.00 | 150.85 |
High Price | Low Price | Open Price | Shares Traded | Last Trade |
---|---|---|---|---|
152.60 | 149.05 | 150.75 | 891 | 22:50:14 |
Date | Time | Source | Headline |
---|---|---|---|
19/11/2024 | 06:00 | UKREG | Dapirolizumab Pegol Phase 3 Data Presented at the American College of.. |
14/11/2024 | 16:23 | UKREG | Eisai Receives Positive Opinion from the CHMP in the European Union for.. |
30/10/2024 | 23:30 | UKREG | Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting.. |
29/10/2024 | 22:00 | UKREG | Biogen and Neomorph Announce Multi-Target Research Collaboration to.. |
29/10/2024 | 12:00 | UKREG | Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer |
28/10/2024 | 12:30 | UKREG | Michael McDonnell, Executive Vice President and Chief Financial Officer to.. |
27/10/2024 | 00:15 | UKREG | Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in.. |
24/10/2024 | 11:30 | UKREG | Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease.. |
22/10/2024 | 11:30 | UKREG | Biogen Announces Late Breaker and New Data Presentations at American.. |
09/10/2024 | 11:30 | UKREG | Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab.. |
1 Year Biogen Chart |
Intraday Biogen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions